# National Institute of Diabetes and Digestive and Kidney Diseases

**Type:** Funders  
**Canonical URL:** https://scholariq.org/funders/national-institute-of-diabetes-and-digestive-and-kidney-diseases/

## Facts

| Field | Value |
| --- | --- |
| Country | US |
| Description | institute of the National Institutes of Health in the United States |
| OpenAlex ID | https://openalex.org/F4320337357 |
| ROR ID | https://ror.org/00adh9b73 |
| Works | 343,847 |

## Funder papers

Showing 15 of 81.

- [Glucose Control and Vascular Complications in Veterans with Type 2 Diabetes](https://scholariq.org/papers/glucose-control-and-vascular-complications-in-veterans-with-type-2-diabetes/)
- [Development and Validation of the American Heart Association’s PREVENT Equations](https://scholariq.org/papers/development-and-validation-of-the-american-heart-association-s-prevent-equations/)
- [Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases](https://scholariq.org/papers/executive-summary-of-the-kdigo-2021-guideline-for-the-management-of-glomerular/)
- [Polycystic kidney disease](https://scholariq.org/papers/polycystic-kidney-disease-2/)
- [Podocytopathies](https://scholariq.org/papers/podocytopathies/)
- [Addition of Angiotensin Receptor Blockade or Mineralocorticoid Antagonism to Maximal Angiotensin-Converting Enzyme Inhibition in Diabetic Nephropathy](https://scholariq.org/papers/addition-of-angiotensin-receptor-blockade-or-mineralocorticoid-antagonism-to/)
- [Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction](https://scholariq.org/papers/efficacy-of-dapagliflozin-on-renal-function-and-outcomes-in-patients-with-heart/)
- [Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups](https://scholariq.org/papers/canagliflozin-and-cardiovascular-and-renal-outcomes-in-type-2-diabetes-mellitus/)
- [Effect of intensive diabetes treatment on albuminuria in type 1 diabetes: long-term follow-up of the Diabetes Control and Complications Trial and Epidemiology of Diabetes Interventions and Complications study](https://scholariq.org/papers/effect-of-intensive-diabetes-treatment-on-albuminuria-in-type-1-diabetes-long/)
- [Plasma Concentrations of Per- and Polyfluoroalkyl Substances at Baseline and Associations with Glycemic Indicators and Diabetes Incidence among High-Risk Adults in the Diabetes Prevention Program Trial](https://scholariq.org/papers/plasma-concentrations-of-per-and-polyfluoroalkyl-substances-at-baseline-and/)
- [Initial Decline (Dip) in Estimated Glomerular Filtration Rate After Initiation of Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction: Insights From DAPA-HF](https://scholariq.org/papers/initial-decline-dip-in-estimated-glomerular-filtration-rate-after-initiation-of/)
- [Predictors of Per- and Polyfluoroalkyl Substance (PFAS) Plasma Concentrations in 6–10 Year Old American Children](https://scholariq.org/papers/predictors-of-per-and-polyfluoroalkyl-substance-pfas-plasma-concentrations-in-6/)
- [KDIGO 2025 clinical practice guideline for the evaluation, management, and treatment of autosomal dominant polycystic kidney disease (ADPKD): executive summary](https://scholariq.org/papers/kdigo-2025-clinical-practice-guideline-for-the-evaluation-management-and/)
- [Identifying Outcomes Important to Patients with Glomerular Disease and Their Caregivers](https://scholariq.org/papers/identifying-outcomes-important-to-patients-with-glomerular-disease-and-their/)
- [Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial](https://scholariq.org/papers/effects-of-empagliflozin-on-progression-of-chronic-kidney-disease-a-prespecified/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.